Philadelphia PennsyIvania, Pennsylvania Clinical Trials

A listing of Philadelphia PennsyIvania, Pennsylvania clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 99 clinical trials
Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency

This study will assess the efficacy and safety of capivasertib plus abiraterone (+prednisone/prednisolone) plus androgen deprivation therapy (ADT) versus placebo plus abiraterone (+prednisone/prednisolone) plus ADT in participants with mHSPC whose tumours are characterised by PTEN deficiency. The intention of the study is to demonstrate that in participants with mHSPC, the …

gonadotropin releasing hormone
bone metastases
androgen suppression
solid tumour
luteinizing hormone-releasing hormone agonist
Research Site
 (8.9 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +106 other locations
A Study Evaluating The Safety Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC).

A study evaluating the safety, preliminary efficacy and pharmacokinetics of ipatasertib in combination with atezolizumab and docetaxel in participants with mCRPC previously treated with second-generation AR (Androgen Receptor)-targeted therapy. The study consists of two parts: [1] Part A: Safety run-in cohort of approximately 12 participants; [2] Part B: Expansion cohort …

progression of prostate cancer
gonadotropin releasing hormone
prostate adenocarcinoma
testosterone
adenopathy
Fox Chase Cancer Center
 (8.9 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +17 other locations
A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD Patients

Primary Objective: To determine the effect of venglustat on the rate of total kidney volume (TKV) growth (Stage and estimated glomerular filtration rate (eGFR) decline in patients at risk of rapidly progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD) (Stage 2). Secondary Objectives: To determine the effect of venglustat on the …

autosomal dominant
chronic kidney disease
antihypertensive therapy
human chorionic gonadotropin
renal function
Investigational Site Number 8400011
 (1.6 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +80 other locations
Phase 2 Study of SAR439859 Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer (AMEERA-3)

Primary Objective: To determine whether SAR439859 per os improves progression free survival (PFS) when compared with a endocrine monotherapy of the choice of the physician, in participants with metastatic or locally advanced breast cancer. Secondary Objectives: To compare the overall survival in the 2 treatment arms To assess the objective …

adenocarcinoma of the breast
HER2
er-positive breast cancer
endocrine therapy
estrogen receptor-positive breast cancer
Investigational Site Number 8400001
 (5.8 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +130 other locations
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis (FREVIVA)  

The purpose of this randomized, double-blind, placebo-controlled, parallel group study is to determine the efficacy of frexalimab in delaying the disability progression and the safety up to approximately 51 months administration of study intervention compared to placebo in male and female participants with nrSPMS (aged 18 to 60 years at …

Comprehensive MS Center Thomas Jefferson University Hospital Site Number : 8400035
 (0.5 away)
  • 0 views
  • 04 Mar, 2025
  • +58 other locations
A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.

This is a multi-center, randomized, double-blind, placebo-controlled, parallel group 36 week multicenter Phase 2 study of two doses of CT1812 in adults with mild to moderate Alzheimer's Disease (AD).

University of Pennsylvania
 (1.6 away) Contact site
  • 0 views
  • 20 Sep, 2024
  • +10 other locations
Anti-GITR/Anti-PD1/Stereotactic Radiosurgery in Recurrent Glioblastoma

This is a phase II study of the combination of the GITR agonist monoclonal antibody INCAGN01876, the anti-PD1 monoclonal antibody INCMGA00012, and stereotactic radiosurgery (SRS) for recurrent Glioblastoma (GBM). The investigators hypothesize that the proposed regimen will be safe and stimulate a robust anti-tumor immune response and result in improved …

stereotactic radiosurgery
glioma
monoclonal antibodies
renal function test
bevacizumab
Hospital of the University of Pennsylvania
 (1.6 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • 1 location
A Study to Test the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

The purpose of the study is to test the efficacy and safety of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS)

antibiotics
antibiotic therapy
abscess
bimekizumab
antibiotic
Hs0004 50150
 (0.5 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +15 other locations
Clinician Communication About Sexual Health

The objective of this study is to adapt a previously tested brief intervention aimed at enhancing clinicians communication about sexual health (iSHARE) to a mobile web-based platform showcasing a two-part podcast and to assess the feasibility, acceptability, and preliminary effects of the intervention in breast cancer clinicians.

Fox Chase Cancer Center
 (8.9 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • 1 location
Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

IMC-F106C is an immune-mobilizing T cell receptor against cancer (ImmTAC ) designed for the treatment of cancers positive for the tumor-associated antigen PRAME. This is a first-in-human trial designed to evaluate the safety and efficacy of IMC-F106C in adult patients who have the appropriate HLA-A2 tissue marker and whose cancer …

Thomas Jefferson University Hospital
 (0.5 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +9 other locations